The Filing Desk

Septerna vs Wave Life Sciences

Septerna SEPN · Wave Life Sciences WVE · Biotechnology

Septerna reported revenue of $46 million in fiscal 2025, about the same as Wave Life Sciences' $43 million in fiscal 2025. Septerna's revenue grew 4174.5% in its latest year, and Wave Life Sciences' fell 60.5%. Septerna had an operating margin of -148.6%, against -504.1% at Wave Life Sciences. Free cash flow was $110 million at Septerna and −$188 million at Wave Life Sciences.

Side by side

SepternaWave Life Sciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$46M$43M
Revenue growth4,174.5%−60.5%
Revenue growth a year, last 5 years—16.3%
Gross margin——
Operating margin−148.6%−504.1%
Net margin−106.4%−478.3%
Free cash flow$110M−$188M
Free cash flow margin238.7%−440.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count347.5%22.0%
Last close$42.60$3.13
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
SepternaWave Life Sciences
Operating margin
Percent of revenue
SepternaWave Life Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
SepternaWave Life Sciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Septerna and Wave Life Sciences pages.